Rheumatoid arthritis

A female challenge

M. Gerosa, V. De Angelis, P. Riboldi, Pier Luigi Meroni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Rheumatoid arthritis (RA) is two- to three-fold more frequent in women than in men and a strong association with sex hormones has been demonstrated. There is strong evidence that autoimmunity is under genetic control, and genes in sexual chromosomes can play a role in supporting the female prevalence. On the other hand, it is widely accepted that sex hormones - estrogens in particular - may regulate the immune response by favoring the survival of forbidden autoreactive clones and ultimately the prevalence of autoimmunity in women. Accordingly, estrogens have been suggested to be associated with the development of RA. Pregnancy in RA women is a common situation and most pregnant patients experience a remission. This has been closely related to a switch from Th1 to Th2 immune responses and to a decreased production of proinflammatory cytokines, at least in part supported by the changes of the hormonal profile in pregnancy. Pregnancy planning is required in RA in order to avoid unwanted complications. In particular, the need to control the disease requires safe use of antirheumatic drugs both during the pregnancy itself and in the breastfeeding period. Hormonal treatment for contraception is contraindicated in the case of positivity for antiphospholipid antibodies owing to the increased thrombophilic risk. Similarly, replacement hormonal treatment in postmenopausal women with RA to control osteoporosis is no longer recommended as a result of its ability to increase the cardiovascular risk closely associated with RA itself.

Original languageEnglish
Pages (from-to)195-201
Number of pages7
JournalWomen's Health
Volume4
Issue number2
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Rheumatoid Arthritis
Pregnancy
Gonadal Steroid Hormones
Autoimmunity
Estrogens
Antiphospholipid Antibodies
Antirheumatic Agents
Aptitude
Breast Feeding
Contraception
Osteoporosis
Clone Cells
Chromosomes
Cytokines
Survival
Therapeutics
Genes

Keywords

  • Autoimmunity
  • Female gender
  • Rheumatoid arthritis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rheumatoid arthritis : A female challenge. / Gerosa, M.; De Angelis, V.; Riboldi, P.; Meroni, Pier Luigi.

In: Women's Health, Vol. 4, No. 2, 03.2008, p. 195-201.

Research output: Contribution to journalArticle

Gerosa, M, De Angelis, V, Riboldi, P & Meroni, PL 2008, 'Rheumatoid arthritis: A female challenge', Women's Health, vol. 4, no. 2, pp. 195-201. https://doi.org/10.2217/17455057.4.2.195
Gerosa, M. ; De Angelis, V. ; Riboldi, P. ; Meroni, Pier Luigi. / Rheumatoid arthritis : A female challenge. In: Women's Health. 2008 ; Vol. 4, No. 2. pp. 195-201.
@article{688b3a620b514ddab0e7545563ef5992,
title = "Rheumatoid arthritis: A female challenge",
abstract = "Rheumatoid arthritis (RA) is two- to three-fold more frequent in women than in men and a strong association with sex hormones has been demonstrated. There is strong evidence that autoimmunity is under genetic control, and genes in sexual chromosomes can play a role in supporting the female prevalence. On the other hand, it is widely accepted that sex hormones - estrogens in particular - may regulate the immune response by favoring the survival of forbidden autoreactive clones and ultimately the prevalence of autoimmunity in women. Accordingly, estrogens have been suggested to be associated with the development of RA. Pregnancy in RA women is a common situation and most pregnant patients experience a remission. This has been closely related to a switch from Th1 to Th2 immune responses and to a decreased production of proinflammatory cytokines, at least in part supported by the changes of the hormonal profile in pregnancy. Pregnancy planning is required in RA in order to avoid unwanted complications. In particular, the need to control the disease requires safe use of antirheumatic drugs both during the pregnancy itself and in the breastfeeding period. Hormonal treatment for contraception is contraindicated in the case of positivity for antiphospholipid antibodies owing to the increased thrombophilic risk. Similarly, replacement hormonal treatment in postmenopausal women with RA to control osteoporosis is no longer recommended as a result of its ability to increase the cardiovascular risk closely associated with RA itself.",
keywords = "Autoimmunity, Female gender, Rheumatoid arthritis",
author = "M. Gerosa and {De Angelis}, V. and P. Riboldi and Meroni, {Pier Luigi}",
year = "2008",
month = "3",
doi = "10.2217/17455057.4.2.195",
language = "English",
volume = "4",
pages = "195--201",
journal = "Women's health (London, England)",
issn = "1745-5065",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Rheumatoid arthritis

T2 - A female challenge

AU - Gerosa, M.

AU - De Angelis, V.

AU - Riboldi, P.

AU - Meroni, Pier Luigi

PY - 2008/3

Y1 - 2008/3

N2 - Rheumatoid arthritis (RA) is two- to three-fold more frequent in women than in men and a strong association with sex hormones has been demonstrated. There is strong evidence that autoimmunity is under genetic control, and genes in sexual chromosomes can play a role in supporting the female prevalence. On the other hand, it is widely accepted that sex hormones - estrogens in particular - may regulate the immune response by favoring the survival of forbidden autoreactive clones and ultimately the prevalence of autoimmunity in women. Accordingly, estrogens have been suggested to be associated with the development of RA. Pregnancy in RA women is a common situation and most pregnant patients experience a remission. This has been closely related to a switch from Th1 to Th2 immune responses and to a decreased production of proinflammatory cytokines, at least in part supported by the changes of the hormonal profile in pregnancy. Pregnancy planning is required in RA in order to avoid unwanted complications. In particular, the need to control the disease requires safe use of antirheumatic drugs both during the pregnancy itself and in the breastfeeding period. Hormonal treatment for contraception is contraindicated in the case of positivity for antiphospholipid antibodies owing to the increased thrombophilic risk. Similarly, replacement hormonal treatment in postmenopausal women with RA to control osteoporosis is no longer recommended as a result of its ability to increase the cardiovascular risk closely associated with RA itself.

AB - Rheumatoid arthritis (RA) is two- to three-fold more frequent in women than in men and a strong association with sex hormones has been demonstrated. There is strong evidence that autoimmunity is under genetic control, and genes in sexual chromosomes can play a role in supporting the female prevalence. On the other hand, it is widely accepted that sex hormones - estrogens in particular - may regulate the immune response by favoring the survival of forbidden autoreactive clones and ultimately the prevalence of autoimmunity in women. Accordingly, estrogens have been suggested to be associated with the development of RA. Pregnancy in RA women is a common situation and most pregnant patients experience a remission. This has been closely related to a switch from Th1 to Th2 immune responses and to a decreased production of proinflammatory cytokines, at least in part supported by the changes of the hormonal profile in pregnancy. Pregnancy planning is required in RA in order to avoid unwanted complications. In particular, the need to control the disease requires safe use of antirheumatic drugs both during the pregnancy itself and in the breastfeeding period. Hormonal treatment for contraception is contraindicated in the case of positivity for antiphospholipid antibodies owing to the increased thrombophilic risk. Similarly, replacement hormonal treatment in postmenopausal women with RA to control osteoporosis is no longer recommended as a result of its ability to increase the cardiovascular risk closely associated with RA itself.

KW - Autoimmunity

KW - Female gender

KW - Rheumatoid arthritis

UR - http://www.scopus.com/inward/record.url?scp=41949130259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949130259&partnerID=8YFLogxK

U2 - 10.2217/17455057.4.2.195

DO - 10.2217/17455057.4.2.195

M3 - Article

VL - 4

SP - 195

EP - 201

JO - Women's health (London, England)

JF - Women's health (London, England)

SN - 1745-5065

IS - 2

ER -